FOR IMMEDIATE RELEASE
IMMUNOTEC ANNOUNCES RECENT CLAIM
VAUDREUIL-DORION, QC, May 29, 2013 - Immunotec Inc. (TSX Venture Exchange: IMM), a Canadian based company and a leader in the wellness industry (the "Company"), today announced that it has recently received a demand letter from Mr. Robert M. Henry, former Chairman of the Board of Directors and CEO of the Company, claiming the amount of approximately $1.1 million in relation to the termination of his employment and other claims on Friday, May 10, 2013.
The Company has retained the services of an experienced labour and employment lawyer to assist and represent it in this matter. While the Company will attempt to reach an amicable and reasonable settlement with Mr. Henry, should this not be possible, it will vigorously defend its interests and those of its shareholders.
About Immunotec Inc.
Immunotec is a world class business opportunity supported by unique scientifically proven products that improve wellness. Headquartered with manufacturing facilities near Montreal, Canada, the Company also has distribution capacities to support its commercial activities in Canada and internationally to the United States, Europe, Mexico and the Caribbean.
The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information: Patrick Montpetit CPA;CA CF, Vice president and Chief
Financial Officer, Immunotec Inc. (450) 510-4527
CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

distributed by